June 23rd 2025
Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Retina Specialists: Join us in Long Beach
July 31, 2025 - August 2, 2025
Register Now!
SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application
View More
Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
September 6, 2025
Register Now!
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D
View More
EyeCon 2025
September 26-27, 2025
Register Now!
Optometrists: Earn COPE CE Credits in Portland or Virtually
October 16-17, 2025
Register Now!
Join us at The Ophthalmology Meeting in Orlando this October
October 18, 2025
Register Now!
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Expert Perspectives on Technological Advances in Cataract Surgery
View More
Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy
View More
Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy
View More
(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs
View More
(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention
View More
Evaluating the change in VA, CMT after early switch of anti-VEGF drugs
July 22nd 2020The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
Intravitreal gene therapy holds promise for novel wet AMD treatment
July 17th 2020An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.
Failed lampalizumab studies offer numerous lessons about GA
March 26th 2018Although the phase III Chroma and Spectri studies for lampalizumab (Genentech), an investigational compound for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD), failed to meet their primary endpoints, numerous lessons can be learned from the study data.